301075 多瑞医药
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-6.484-8.6512.4752.65513.235
总资产报酬率 ROA (%)-2.847-4.8071.9132.34311.208
投入资产回报率 ROIC (%)-4.186-6.2932.0742.44912.454

边际利润分析
销售毛利率 (%)4.07242.41568.55276.98188.608
营业利润率 (%)-54.955-35.6416.6375.30013.860
息税前利润/营业总收入 (%)-46.959-34.3055.2953.31613.853
净利润/营业总收入 (%)-56.165-35.3355.1134.63412.436

收益指标分析
经营活动净收益/利润总额(%)114.00787.82616.70859.91786.991
价值变动净收益/利润总额(%)-1.639-6.84725.6620.054-0.268
营业外收支净额/利润总额(%)0.2660.0100.277-1.101-0.170

偿债能力分析
流动比率 (X)1.2401.2385.0244.47811.611
速动比率 (X)1.1321.1484.7674.25211.455
资产负债率 (%)52.00750.91323.37016.1827.375
带息债务/全部投入资本 (%)23.45221.29819.27812.1962.961
股东权益/带息债务 (%)270.480308.203416.939719.0753,277.070
股东权益/负债合计 (%)84.06686.592308.101516.6751,262.815
利息保障倍数 (X)-5.767-25.609-3.893-1.722836.483

营运能力分析
应收账款周转天数 (天)176.955136.61591.08884.25567.179
存货周转天数 (天)83.696102.593112.82583.04573.544